Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

This study (NEOTORCH-BREAST05) is testing a combination of two HER2-targeted drugs — pyrotinib and trastuzumab — added to standard chemotherapy as a pre-surgery treatment (neoadjuvant therapy) for HER2-positive breast cancer. The goal is to shrink the tumor before surgery for better outcomes. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have been diagnosed with HER2-positive invasive breast cancer confirmed by pathology - Your cancer stage meets specific criteria (T1 with node involvement, or T2–T4 with or without node involvement, without distant spread) - Your performance status (ECOG score) is 0 or 1 - Your major organ function (blood, heart, liver) meets required levels **You may NOT be eligible if...** - You have already received treatment for this breast cancer - You have metastatic (Stage 4) disease - Your heart function or other organ function is inadequate Talk to your doctor to see if this trial is right for you.